OBJECTIVES: Certain estradiol metabolites may play a pivotal role in breast carcinogenesis. Of special interest are the metabolites 2-hydroxyestradiol (2-OHE2), which can react anti-carcinogenically, and 4-hydroxyestradiol (4-OHE1) and 16a-hydroxyestrone (16-OHE1), which may have procarcinogenic potential. In the present study, we have compared for the first time the effect of these metabolites and their parent substance 17beta-estradiol (E2) on proliferation, apoptosis, apoptosis markers and markers of metastatic property of human breast cancer cells. METHODS: MCF-7 cells (human estrogen-receptor positive metastatic breast cancer cell line) were incubated with the estrogens at concentrations of 0.1-100 nM. Cell proliferation rate was measured by the ATP-assay. Apoptosis was measured by cell death assay and the apoptosis markers cytochrome C, Bcl-2, Fasl and p53 were determined in cell lysates by ELISAs. The markers of metastatic property of the cell line, VEGF and MCP-1 were measured in the cell supernatant by ELISAs. RESULTS: The estrogens E2, 4-OHE2 and 16-OHE1 display a proliferative effect on MCF-7 cells which is accompanied by a down-regulation of apoptosis. Various markers of apoptosis such as Bcl-2, cytochrome C and p53 appear to be involved. No significant effect was found for the metabolite 2-OHE2. VEGF and MCP-1 were up-regulated by E2 and 16-OHE1, whereas 2-OHE2 and 4-OHE2 did not show any effect. CONCLUSIONS: The most potent estrogen regarding proliferation, apoptosis and metastasis of breast cancer cells seems to be estradiol. However, the estradiol metabolites 4-OHE2 and 16-OHE1 elicit similar properties on cell proliferation, apoptosis and metastasis as compared to estradiol but only at higher concentrations. In contrast 2-OHE2 did not show any significant effect on these parameters. Thus, intracellular estradiol metabolism may determine an individual's risk for breast carcinogenesis.
OBJECTIVES: Certain estradiol metabolites may play a pivotal role in breast carcinogenesis. Of special interest are the metabolites 2-hydroxyestradiol (2-OHE2), which can react anti-carcinogenically, and 4-hydroxyestradiol (4-OHE1) and 16a-hydroxyestrone (16-OHE1), which may have procarcinogenic potential. In the present study, we have compared for the first time the effect of these metabolites and their parent substance 17beta-estradiol (E2) on proliferation, apoptosis, apoptosis markers and markers of metastatic property of humanbreast cancer cells. METHODS: MCF-7 cells (human estrogen-receptor positive metastatic breast cancer cell line) were incubated with the estrogens at concentrations of 0.1-100 nM. Cell proliferation rate was measured by the ATP-assay. Apoptosis was measured by cell death assay and the apoptosis markers cytochrome C, Bcl-2, Fasl and p53 were determined in cell lysates by ELISAs. The markers of metastatic property of the cell line, VEGF and MCP-1 were measured in the cell supernatant by ELISAs. RESULTS: The estrogens E2, 4-OHE2 and 16-OHE1 display a proliferative effect on MCF-7 cells which is accompanied by a down-regulation of apoptosis. Various markers of apoptosis such as Bcl-2, cytochrome C and p53 appear to be involved. No significant effect was found for the metabolite 2-OHE2. VEGF and MCP-1 were up-regulated by E2 and 16-OHE1, whereas 2-OHE2 and 4-OHE2 did not show any effect. CONCLUSIONS: The most potent estrogen regarding proliferation, apoptosis and metastasis of breast cancer cells seems to be estradiol. However, the estradiol metabolites 4-OHE2 and 16-OHE1 elicit similar properties on cell proliferation, apoptosis and metastasis as compared to estradiol but only at higher concentrations. In contrast 2-OHE2 did not show any significant effect on these parameters. Thus, intracellular estradiol metabolism may determine an individual's risk for breast carcinogenesis.
Authors: A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler Journal: Cancer Res Date: 2011-12-05 Impact factor: 12.701
Authors: Cher M Dallal; Jeffrey A Tice; Diana S M Buist; Douglas C Bauer; James V Lacey; Jane A Cauley; Trisha F Hue; Andrea Lacroix; Roni T Falk; Ruth M Pfeiffer; Barbara J Fuhrman; Timothy D Veenstra; Xia Xu; Louise A Brinton Journal: Carcinogenesis Date: 2013-11-08 Impact factor: 4.944
Authors: Renée T Fortner; Hannah Oh; Sarah E Daugherty; Xia Xu; Susan E Hankinson; Regina G Ziegler; A Heather Eliassen Journal: Horm Cancer Date: 2014-01-10 Impact factor: 3.869
Authors: Julia S Sisti; Susan E Hankinson; Neil E Caporaso; Fangyi Gu; Rulla M Tamimi; Bernard Rosner; Xia Xu; Regina Ziegler; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Nikola Getoff; Heike Schittl; Marion Gerschpacher; Johannes Hartmann; Johannes C Huber; Ruth-Maria Quint Journal: In Vivo Date: 2010 Mar-Apr Impact factor: 2.155
Authors: Anna Ptak; Gabriele Ludewig; Agnieszka Rak; Weronika Nadolna; Michał Bochenek; Ewa L Gregoraszczuk Journal: Environ Int Date: 2009-07-14 Impact factor: 9.621
Authors: Steven C Moore; Charles E Matthews; Xiao Ou Shu; Kai Yu; Mitchell H Gail; Xia Xu; Bu-Tian Ji; Wong-Ho Chow; Qiuyin Cai; Honglan Li; Gong Yang; David Ruggieri; Jennifer Boyd-Morin; Nathaniel Rothman; Robert N Hoover; Yu-Tang Gao; Wei Zheng; Regina G Ziegler Journal: J Natl Cancer Inst Date: 2016-05-18 Impact factor: 13.506
Authors: Hannah Oh; Zeina G Khodr; Mark E Sherman; Maya Palakal; Ruth M Pfeiffer; Laura Linville; Berta M Geller; Pamela M Vacek; Donald L Weaver; Rachael E Chicoine; Roni T Falk; Hisani N Horne; Daphne Papathomas; Deesha A Patel; Jackie Xiang; Xia Xu; Timothy Veenstra; Stephen M Hewitt; John A Shepherd; Louise A Brinton; Jonine D Figueroa; Gretchen L Gierach Journal: Horm Cancer Date: 2016-05-02 Impact factor: 3.869
Authors: A Heather Eliassen; Stacey A Missmer; Shelley S Tworoger; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254